Big drug maker Gilead expects to take a billion-dollar hit this year via drug-pricing provisions in the Inflation Reduction ...

HIV prevention shot achieved a 96% success rate in clinical trials, but accessibility and regulatory hurdles remain a ...

Descovy and Truvada are prescription drugs used to treat and help prevent HIV. Both drugs come as oral tablets that are taken once per day. Truvada is available as a generic drug, while Descovy is ...

The long-running HIV market rivalry between Gilead Sciences and GSK is about to turn a new page this year as Gilead looks to ...

Gilead Sciences Inc. sees 2025 earnings rising faster than Wall Street expected after a big fourth-quarter beat highlighted ...

Two oral PrEP medications have been approved by the U.S. Food and Drug Administration (FDA)—Truvada and Descovy—and one injection drug called Apretude that must be taken once every two months.

(Descovy wasn’t available in time for that ... for men at high risk of acquiring HIV through unprotected sex or injection drug use. Truvada is also approved for women. But fewer than 1 in ...

Gilead’s Descovy got a green light from an FDA advisory committee for HIV pre-exposure prophylaxis (PrEP) yesterday – but as expected its use in women was a point of contention. Descovy ...

Gilead Sciences has filed Descovy, its successor to HIV pre-exposure prophylaxis (PrEP) therapy Truvada, in the US, spending a priority review voucher (PRV) to set up a verdict within six months.

In this month’s issue, the Sexpert advises readers on how to navigate discussions of PrEP and sexual health while in the ...

Jan 15 (Reuters) - Gilead Sciences (GILD.O), opens new tab and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs Truvada and Descovy, according to ...